An asthmatic case of psoriasiform eruption caused by administration of dupilumab

Dear Editor, Dupilumab is a humanized IgG4 monoclonal antibody that targets the IL-4 receptor alpha chain and inhibits type 2 inflammation. It is suitable for atopic dermatitis and asthma therapy and injected subcutaneously every two weeks. Some side effects reported to date are injection site reactions, conjunctivitis, and rarely anaphylaxis. Here, we present a patient with severe asthma who experienced the onset of psoriasis after treatment with dupilumab. Details of this case from the viewpoint of mechanisms connecting dupilumab and the pathophysiology of psoriasis are given. He gave us written informed consent for publication of this case report. A 60-year-old man had been diagnosed with asthma and treated with an inhalation therapy of inhaled corticosteroids (ICS), long-acting beta agonist (LABA), and long-acting muscarinic antagonist (LAMA) for 6 years at our hospital.